Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma

Glioblastoma is the most common and aggressive primary tumor of the central nervous system with poor outcome. Current gold standard treatment is surgical resection followed by a combination of radio- and chemotherapy. Efficacy of temozolomide (TMZ), the primary chemotherapeutic agent, depends on the...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xinyu Han, Mohammed O.E. Abdallah, Peter Breuer, Fabian Stahl, Yousuf Bakhit, Anna-Laura Potthoff, Barbara E.F. Pregler, Matthias Schneider, Andreas Waha, Ullrich Wüllner, Bernd O. Evert
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2023-10-01
coleção:	Neoplasia: An International Journal for Oncology Research
Assuntos:	CRISPR/Cas9 technology MGMT Temozolomide Glioblastoma
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1476558623000532
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!